Publications

Breast cancer research : BCR

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.

13-11-2023

BMJ (Clinical research ed.)

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

30-10-2023

Cell reports. Medicine

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2⁺ breast cancer.

17-10-2023

European journal of cancer (Oxford, England : 1990)

Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.

01-10-2023

NPJ breast cancer

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.

09-09-2023

British journal of cancer

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.

01-09-2023

Cell

Archival single-cell genomics reveals persistent subclones during DCIS progression.

31-08-2023

Breast cancer research : BCR

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.

19-06-2023

Scientific reports

Microcalcification crystallography as a potential marker of DCIS recurrence.

08-06-2023

Cancer cell

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

08-05-2023

Nature communications

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

07-04-2023

British journal of cancer

Tumour-educated platelets for breast cancer detection: biological and technical insights.

01-04-2023

Nature reviews. Cancer

Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-02-2023

Breast cancer research and treatment

Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.

01-01-2023

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.

01-12-2022

Nature reviews. Cancer

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-12-2022

Journal of geriatric oncology

Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.

01-11-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.

14-10-2022

Breast (Edinburgh, Scotland)

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival.

01-10-2022

British journal of cancer

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.

01-10-2022

Key Publication

The Lancet. Oncology

De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.

01-09-2022

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.

20-07-2022

Cancers

Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review.

02-07-2022

The Journal of pathology

Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology.

01-07-2022

Nature genetics

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

01-06-2022

Key Publication

NPJ breast cancer

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

06-05-2022

Key Publication

Radiology

Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features.

01-04-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

01-03-2022

Breast cancer research : BCR

Common variants in breast cancer risk loci predispose to distinct tumor subtypes.

04-01-2022

The Lancet. Oncology

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

01-01-2022

Breast (Edinburgh, Scotland)

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients.

01-12-2021

Annals of surgical oncology

Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.

01-11-2021

British journal of cancer

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.

01-11-2021

NPJ breast cancer

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

20-10-2021

Preventive medicine

Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic.

01-10-2021

Cancers

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists.

06-08-2021

Breast cancer research and treatment

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.

01-08-2021

The British journal of radiology

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer.

01-07-2021

JAMA oncology

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.

01-07-2021

The journal of pathology. Clinical research

Variability in grading of ductal carcinoma in situ among an international group of pathologists.

01-05-2021

Breast cancer research and treatment

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?

01-05-2021

Journal of hematology & oncology

Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study.

17-04-2021

NPJ breast cancer

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

22-03-2021

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

The Way of the Future: Personalizing Treatment Plans Through Technology.

01-03-2021

European radiology

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index.

01-12-2020

Journal of hematology & oncology

The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands.

04-11-2020

NPJ breast cancer

Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer.

03-11-2020

Nature reviews. Clinical oncology

Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.

01-11-2020

Nature reviews. Clinical oncology

Personalized early detection and prevention of breast cancer: ENVISION consensus statement.

01-11-2020

Breast cancer research and treatment

Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.

01-10-2020

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer.

Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.

Archival single-cell genomics reveals persistent subclones during DCIS progression.

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.

Microcalcification crystallography as a potential marker of DCIS recurrence.

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

Tumour-educated platelets for breast cancer detection: biological and technical insights.

Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study.

Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.

Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival.

Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.

De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.

Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review.

Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology.

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

Common variants in breast cancer risk loci predispose to distinct tumor subtypes.

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients.

Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic.

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists.

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer.

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.

Variability in grading of ductal carcinoma in situ among an international group of pathologists.

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?

Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study.

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.

The Way of the Future: Personalizing Treatment Plans Through Technology.

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index.

The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands.

Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer.

Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.

Personalized early detection and prevention of breast cancer: ENVISION consensus statement.

Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.

This site uses cookies

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2⁺ breast cancer.